Shannon Heaning, Content Associate

Jennifer Soung, MD, discussed whole-person care for psoriasis and alopecia areata and emerging conversations around skin aging and menopause.

Verrica Pharmaceuticals has completed enrollment in COVE-2, its first pivotal phase 3 trial of YCANTH for common warts, with topline data expected in the first quarter of 2027.

As NPs and PAs take on more dermatology care, specialty certification remains limited despite growing opportunities for advanced training.

A meta-analysis found significantly lower SCC risk in patients with vitiligo, offering useful context for skin cancer and phototherapy counseling.

Stephanie Kauffman, chief executive officer of the Melanoma Research Alliance, discussed funding strategy, early career researcher support, and melanoma prevention in a recent Dermatology Times interview.

Daniel Butler, MD, discusses the 5Ms of geriatric care, shared decision-making, deprescribing, and emerging approaches to chronic itch.

Rezpegaldesleukin improved EASI, itch, and other outcomes in phase 2b REZOLVE-AD, supporting continued phase 3 development.

Lisa Weiss, PA-C, discussed why continuous learning and conference attendance remain valuable for dermatology PAs at every career stage.

A patient is thriving on JAK inhibitor therapy—then her LDL spikes. Work through the case and decide what you would do next.

Test your knowledge of Tudriqev’s accelerated approval, clinical activity, administration, and ongoing confirmatory research.

Imsidolimab gained EU orphan designation for GPP as the IL-36 receptor inhibitor advances toward a December 2026 FDA decision.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Victoria Garcia-Albea, NP, discussed the learning curve for dermatology NP fellows and how continued education parallels the evolution of the specialty.

Eileen Cheever, PA, shared how mentorship, experienced colleagues, and conference attendance can support professional growth and patient care.

A practical guide to baseline testing, follow-up laboratory monitoring, and managing abnormalities in patients receiving oral JAK inhibitors.

Stay ahead with a weekly roundup of the biggest practice management, AI, policy, business, and professional development updates in dermatology.

Stephanie Kauffman, CEO of the Melanoma Research Alliance, discussed the organization's research priorities as it approaches 20 years of advancing melanoma research.

Goran Mićević, MD, PhD, joined Christopher Bunick, MD, PhD, to discuss phase 3 findings showing an individualized mRNA neoantigen therapy improved outcomes with checkpoint blockade in resected melanoma.

MotherToBaby launched a pregnancy study to address limited safety data for lebrikizumab use in patients with atopic dermatitis.

Preclinical data show GX-03 reduced IL-31 by nearly 68% and dermatitis severity by 66% in a murine model of atopic dermatitis.

Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.

Jennifer Song, MD, discussed icotrokinra, expanding pediatric psoriasis options, emerging TYK2 inhibitors, and GLP-1 combination data.

Daniel Butler, MD, discussed how aging affects psoriasis presentation and the insurance challenges facing older patients in a recent Dermatology Times interview.

Judson Brewer, MD, PhD, discussed how the trigger-behavior-result habit loop model can be applied to itch-scratch cycles in atopic dermatitis.

LEO Pharma will acquire worldwide rights to dersimelagon, an investigational oral therapy under FDA review for EPP and XLP.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Updated Allergan Partner Privileges offers simplified savings, greater benefits transparency, portfolio-level rewards, and a new BOTOX Cosmetic growth rebate.

Chantel K. Hillestad, MSN, DCNP, FNP-C, discusses recurrent MCC, treatment access, and care coordination for patients in rural communities.

Review common questions about psoriasis, including systemic disease, PsA screening, treatment selection, triggers, and patient counseling.

Long-term envudeucitinib data showed increasing skin clearance through 48 weeks, with 54% of continuously treated patients achieving PASI 100.